We recently compiled a list of the Jim Cramer Discussed These 11 Stocks Before The DeepSeek Sell-Off. In this article, we are ...

The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals.

Although RMD has re-rated from its share price low of around $21.50 in October 2023, it has only just surpassed its all-time ...

Mohit Bansal, an analyst from Wells Fargo, assigned the Buy rating on Ironwood Pharma (IRWD – Research Report). The associated price target is ...

Azenta, Inc. (Nasdaq: AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA) ...

The heads of The RMR Group, Lupoli Cos. and National Development share their investment and development priorities for 2025.

Though deal value is down, volume is stable (with biopharma deals +17% vs. 2023), but average deal size dropped, as companies shifted focus to look for earlier-stage opportunities with lower price ...

BURLINGTON, Mass. - Azenta, Inc. (NASDAQ: AZTA), a global provider of life sciences solutions, announced the election of ...

Broadcom Inc. (AVGO), and Motorola Solutions (MSI). This theme touches a select group of stocks in almost every industry. We have built two investment products that leverage this theme: a UIT with our ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...